BioSpace News Archive

AdvantEdge Healthcare Solutions (“AdvantEdge”), a national leading healthcare billing, coding, and practice management company, today announced successful third party recertification for HIPAA and HITECH privacy and security requirements by 360 Advanced as well as SOC 1 Type 2 and SOC 2 Type 2 for information security and transparency

Mirum Pharmaceuticals today announced the presentation of Phase 2 clinical data at The International Liver Congress™ 2019, demonstrating the potential of maralixibat, the company’s lead product candidate, to durably improve clinical outcomes for children with progressive familial intrahepatic cholestasis type 2 (PFIC2) and Alagille syndrome.

Mr. Sachdev is currently Executive Vice President and Chief Regulatory Officer at Vertex Pharmaceuticals Incorporated, where he serves on its Executive Committee and has been an executive officer since 2007.

PracticeWise, a behavioral health company that helps those who are in the business of helping others lead better lives, today announced the formation of its inaugural Advisory Board and appointment of members.

San Diego-based Allele Biotechnology and Pharmaceuticals, Inc., officially announced a joint research and development agreement with South Korea’s SCM Lifescience Co., Ltd., for the development of diabetes therapies using pancreatic beta cells derived from induced pluripotent stem cells.

A New Collaboration between FAIR Health and the Colorado Division of Workers’ Compensation

Zymeworks Inc. announced it has initiated its global multicenter Phase 2 clinical trial evaluating ZW25 in combination with standard of care chemotherapy for the first-line treatment of HER2-positive metastatic gastric, gastroesophageal junction, and esophageal adenocarcinomas.

QIAGEN N.V. plans as previously announced to release its report on results for the first quarter 2019 on Monday, May 6 at approximately 22:05 Central European Time / 16:05 Eastern Standard Time.

Reference library expansion for broader species identification by MALDI Biotyper (MBT)

Soligenix, Inc. announced that it has received approximately $611,000, net of transaction costs, in non-dilutive financing via the state of New Jersey’s Technology Business Tax Certificate Transfer Program.